Medical Condition News

RSS

Exagen Diagnostics, EndoChoice announce agreement for promoting diagnostic services to U.S. gastroenterologists

Exagen Diagnostics, Inc., a molecular diagnostics laboratory that discovers, develops and markets proprietary genomic tests, today announced an exclusive sales and marketing agreement with EndoChoice, Inc. to promote its diagnostic services to gastroenterologists throughout the United States.

17 Feb 2010

Research assesses the overall efficacy of palliative chest RT in patients with advanced NSCLC

Research published in the February edition of the Journal of Thoracic Oncology sought to assess the overall efficacy of split-course palliative chest radiotherapy (RT) for symptom relief in patients with advanced non-small cell lung cancer. Additionally, researchers investigated the impact the regimen's two-week break has on survival outcomes.

17 Feb 2010

First field study shows lack of exposure to morning light delays sleep in teenagers

The first field study on the impact of light on teenagers' sleeping habits finds that insufficient daily morning light exposure contributes to teenagers not getting enough sleep.

17 Feb 2010

Right-ventricular impairment increases risk of death in heart-failure patients

New research from the University of Alabama at Birmingham (UAB) suggests that the ability of right side of the heart to pump blood may be an indication of the risk of death to heart-failure patients whose condition is caused by low function by the left side of their heart.

17 Feb 2010

ViewRay earns NorTech Innovation Award for advancements in cancer radiation therapy technology

ViewRay, Inc., a privately held medical device company, has earned a NorTech Innovation Award for its advancements in radiation therapy technology for the treatment of cancer. ViewRay was honored for its unique combination of medical imaging and radiotherapy, which is designed to improve the effectiveness of cancer treatments. Radiation therapy is used to treat nearly two-thirds of today's cancer patients.

17 Feb 2010

Oxytocin hormone improves social behavior in autistic patients

Autism is a disease characterized by difficulties in communicating effectively with other people and developing social relationships. The team led by Angela Sirigu at the Centre de Neuroscience Cognitive (CNRS) has shown that the inhalation of oxytocin, a hormone known to promote mother-infant bonds and social relationships, significantly improved the abilities of autistic patients to interact with other individuals.

17 Feb 2010

Generx clinical development opportunities: bioRASI to assist Cardium

Cardium Therapeutics today announced that it has entered into an agreement with bioRASI, an international contract research organization, to assist Cardium in the evaluation of Generx clinical development opportunities within major newly-industrializing markets in Eastern Europe, Asia and Latin America, for patients with chronic coronary artery disease who are either not optimal candidates for or do not have access to costly angioplasty/stenting or cardiac bypass surgery procedures.

17 Feb 2010

TKS4 protein plays significant role in Frank-Ter Haar syndrome

An international team of investigators at Sanford-Burnham Medical Research Institute (Sanford-Burnham, formerly Burnham Institute for Medical Research), Nijmegen Centre for Molecular Life Sciences and other organizations have discovered that TKS4, a protein implicated in cancer metastasis, also plays a significant role in Frank-Ter Haar syndrome (FTHS), a rare fatal disorder.

17 Feb 2010

Rhubarb may have anti-cancer properties, but more research needed

Rhubarb contains natural chemicals called polyphenols that have been shown to kill cancer cells in the lab, or prevent their growth. Baking appears to greatly increase the levels of these chemicals, UK scientists have found, but Cancer Research UK cautioned against reading too much into these results.

17 Feb 2010

Adding daclizumab to standard treatment reduces enlarged brain lesions in patients with relapsing MS

An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.

17 Feb 2010

Researchers adopt new technique to inhibit cancer growth

One of the difficulties of fighting cancer is that drugs often hit other non-cancerous cells, causing patients to get sick. But what if researchers could sneak cancer-fighting particles into just the cancer cells?

17 Feb 2010

Quintiles' anatomic pathology services now available in China to help develop effective cancer treatments

Quintiles today announced the availability of anatomic pathology services through its central laboratory in Beijing, China, to help biopharmaceutical companies develop more effective cancer treatments. These services complement assay development, digital pathology and core lab offerings available through the facility to help customers comply with China’s restrictions on tissue import/export.

17 Feb 2010

Certain patients with IBD at increased risk of developing colorectal cancer: AGA's new guidelines

Certain patients with inflammatory bowel disease (IBD), both ulcerative colitis and Crohn's disease of the colon, have an increased risk of developing colorectal cancer compared to individuals without IBD. A number of factors contribute to the increase in risk, which necessitates an individualized and sensible approach to surveillance in patients, according to a new medical position statement and technical review published by the American Gastroenterological Association in its official journal, Gastroenterology.

17 Feb 2010

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

Biogen Idec and Facet Biotech Corporation today announced the publication of Phase 2 data showing that the addition of daclizumab to interferon beta (IFNβ) led to a significant reduction in the number of new or enlarged multiple sclerosis (MS) lesions when compared to IFNβ alone in patients with active relapsing forms of MS.

17 Feb 2010

Controlled utility study results of BGM Galectin-3 test for heart failure published in cardiology journal

BG Medicine, Inc. announced today that the results of a controlled study on the utility of its galectin-3 test in heart failure were published in the Journal Clinical Research in Cardiology, a peer-reviewed, international journal that publishes original research and review articles on clinical research studies in the field of cardiology.

17 Feb 2010

Delayed introduction of complementary baby foods may influence weight: Study

Benjamin Franklin's advice that "an ounce of prevention is worth a pound of cure" can easily be applied to today's most pressing health issue: obesity. Because taking off extra weight is an almost insurmountable challenge, preventing the progression of weight gain throughout life, especially childhood, is crucial to realizing optimal long-term health.

17 Feb 2010

New fluorescent probes improve tumor detection in mice

Building on his Nobel Prize-winning work creating fluorescent proteins that light up the inner workings of cells, a team of researchers led by Howard Hughes Medical Institute investigator Roger Tsien, PhD, professor of pharmacology, chemistry and biochemistry at the University of California, San Diego and the Moores UCSD Cancer Center has developed biological probes that can stick to and light up tumors in mice.

17 Feb 2010

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).

17 Feb 2010

Special issue reviews current state of science in fetal therapy

Repairing birth defects in the womb. Inserting a tiny laser into the mother's uterus to seal off an abnormal blood flow and save fetal twins. Advancing the science that may allow doctors to deliver cells or DNA to treat sickle cell anemia and other genetic diseases before birth.

17 Feb 2010

Quark Pharmaceuticals' QPI-1002 receives orphan drug designation from FDA

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today that the US FDA has granted orphan drug designation for QPI-1002 (also referred to as "I5NP"), a synthetic siRNA targeting p53 mRNA for the prophylaxis of delayed graft function (DGF) in kidney transplant patients.

17 Feb 2010

Medical Condition News

Exagen Diagnostics, EndoChoice announce agreement for promoting diagnostic services to U.S. gastroenterologists

Research assesses the overall efficacy of palliative chest RT in patients with advanced NSCLC

First field study shows lack of exposure to morning light delays sleep in teenagers

Right-ventricular impairment increases risk of death in heart-failure patients

ViewRay earns NorTech Innovation Award for advancements in cancer radiation therapy technology

Oxytocin hormone improves social behavior in autistic patients

Generx clinical development opportunities: bioRASI to assist Cardium

TKS4 protein plays significant role in Frank-Ter Haar syndrome

Rhubarb may have anti-cancer properties, but more research needed

Adding daclizumab to standard treatment reduces enlarged brain lesions in patients with relapsing MS

Researchers adopt new technique to inhibit cancer growth

Quintiles' anatomic pathology services now available in China to help develop effective cancer treatments

Certain patients with IBD at increased risk of developing colorectal cancer: AGA's new guidelines

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

Controlled utility study results of BGM Galectin-3 test for heart failure published in cardiology journal

Delayed introduction of complementary baby foods may influence weight: Study

New fluorescent probes improve tumor detection in mice

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

Special issue reviews current state of science in fetal therapy

Quark Pharmaceuticals' QPI-1002 receives orphan drug designation from FDA

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News